Is the TB-500 fragment the same as full thymosin β-4?

No. It is a short piece built around the actin-binding motif. The full clinically studied molecule is much longer, and the two should not be treated as equivalent.

Why does this distinction matter?

Because most "TB-500" marketing cites data from full thymosin β-4 while the product in the vial may be only the fragment — so the evidence used to sell it may not apply to what you receive.

In vitroResearch compound

TB-500 Fragment

Also known as: Tβ4 fragment, Actin-binding domain peptide, LKKTETQ-containing fragment

The short, actin-binding fragment that most "TB-500" products actually contain — frequently confused with the full thymosin β-4 molecule used in clinical research.

Injectable

Last updated June 19, 2026

This is what most "TB-500" vials actually contain — the short actin-binding fragment, not the full thymosin β-4 from the research. The two get sold as if they were the same molecule. They are not, and the fragment on its own has almost no direct evidence behind it.

Mechanism

Full thymosin β-4 (Tβ4) is a 43–amino-acid peptide, and its actin-binding action is concentrated in one short internal stretch built around the motif LKKTETQ. A lot of "TB-500" on the market is just that fragment, not the whole molecule. The fragment keeps some of the actin-regulating, cell-migration activity in a dish — but it is not the same thing as the full peptide that went through preclinical and early human work.

What the research shows

This is the thinnest evidence base in the cluster, and that is exactly why it earns its own page. The fragment commonly sold as "TB-500" is not the molecule that was clinically studied, yet the two are marketed as interchangeable. Direct, peer-reviewed studies of the standalone consumer fragment are scarce; most of the claims quietly borrow data from full Tβ4. Buyers usually have no idea which one is in the vial. We grade the fragment's own evidence as in-vitro at best, and we treat the labeling confusion as the headline risk — not a side note.

Evidence grade: In vitro — Cell- or tissue-culture evidence only — far from clinical proof.

Benefits studied

Actin-binding and cell-migration activity from the LKKTETQ motif, shown in vitro
Repair-related signals borrowed from full thymosin β-4 research — not demonstrated for the fragment itself

Risks & unknowns

Routinely sold as "TB-500" but is not the full clinically studied thymosin β-4
Very little direct peer-reviewed evidence for the standalone fragment
Label/identity confusion means buyers often cannot tell what they purchased
No human efficacy or long-term safety data; banned in sport by WADA

Regulatory status

Research compound. Sold "for research use only" — not approved for human consumption.

Goals studied: Tendon & ligament repair, Muscle recovery

FAQ

Is the TB-500 fragment the same as full thymosin β-4?: No. It is a short piece built around the actin-binding motif. The full clinically studied molecule is much longer, and the two should not be treated as equivalent.
Why does this distinction matter?: Because most "TB-500" marketing cites data from full thymosin β-4 while the product in the vial may be only the fragment — so the evidence used to sell it may not apply to what you receive.

Sources

[1]
Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues
Goldstein AL, Hannappel E, Kleinman HK · Trends in Molecular Medicine · 2005 · PMID 16099219 · model: in-vitro
Revue expliquant comment ce peptide séquestreur d'actine devient un signal de réparation extracellulaire lorsqu'il est libéré après une lésion.